FR06C0014I2 - - Google Patents

Info

Publication number
FR06C0014I2
FR06C0014I2 FR06C0014C FR06C0014C FR06C0014I2 FR 06C0014 I2 FR06C0014 I2 FR 06C0014I2 FR 06C0014 C FR06C0014 C FR 06C0014C FR 06C0014 C FR06C0014 C FR 06C0014C FR 06C0014 I2 FR06C0014 I2 FR 06C0014I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR06C0014C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of FR06C0014I1 publication Critical patent/FR06C0014I1/fr
Application granted granted Critical
Publication of FR06C0014I2 publication Critical patent/FR06C0014I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR06C0014C 1995-03-27 2006-04-04 Active FR06C0014I2 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number Publication Date
FR06C0014I1 FR06C0014I1 (cg-RX-API-DMAC10.html) 2006-11-17
FR06C0014I2 true FR06C0014I2 (cg-RX-API-DMAC10.html) 2006-12-29

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
FR06C0014C Active FR06C0014I2 (cg-RX-API-DMAC10.html) 1995-03-27 2006-04-04

Country Status (25)

Country Link
US (1) US5900431A (cg-RX-API-DMAC10.html)
EP (1) EP0817626B1 (cg-RX-API-DMAC10.html)
JP (1) JP3260378B2 (cg-RX-API-DMAC10.html)
KR (1) KR100286920B1 (cg-RX-API-DMAC10.html)
CN (1) CN1072485C (cg-RX-API-DMAC10.html)
AP (1) AP646A (cg-RX-API-DMAC10.html)
AT (1) ATE172641T1 (cg-RX-API-DMAC10.html)
AU (1) AU706161B2 (cg-RX-API-DMAC10.html)
CA (1) CA2216623C (cg-RX-API-DMAC10.html)
CZ (1) CZ286821B6 (cg-RX-API-DMAC10.html)
DE (1) DE69600879T2 (cg-RX-API-DMAC10.html)
DK (1) DK0817626T3 (cg-RX-API-DMAC10.html)
EA (1) EA000150B1 (cg-RX-API-DMAC10.html)
ES (1) ES2128846T3 (cg-RX-API-DMAC10.html)
FR (1) FR06C0014I2 (cg-RX-API-DMAC10.html)
HU (1) HU224028B1 (cg-RX-API-DMAC10.html)
IS (1) IS2048B (cg-RX-API-DMAC10.html)
NO (1) NO315968B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ304906A (cg-RX-API-DMAC10.html)
OA (1) OA10515A (cg-RX-API-DMAC10.html)
PL (1) PL183378B1 (cg-RX-API-DMAC10.html)
SK (1) SK283883B6 (cg-RX-API-DMAC10.html)
TR (1) TR199701048T1 (cg-RX-API-DMAC10.html)
UA (1) UA41446C2 (cg-RX-API-DMAC10.html)
WO (1) WO1996030010A2 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0817626T3 (da) * 1995-03-27 1999-07-12 Assist Publ Hopitaux De Paris Anvendelse af fumagillol og derivater deraf til fremstilling af lægemidler mod tarminfektioner
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
WO2000050084A1 (fr) * 1999-02-26 2000-08-31 Sanofi-Synthelabo Formulation stable contenant de la fumagilline
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
WO2009073445A2 (en) * 2007-11-28 2009-06-11 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
NZ590732A (en) * 2008-07-18 2012-09-28 Zafgen Inc Methods of treating an overweight or obese subject using fumagillin
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
EP2486004B1 (en) 2009-10-09 2017-05-03 Zafgen, Inc. Sulphone compounds for use in the treatment of obesity
WO2011085201A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Fumagillol type compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012075020A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
WO2012103333A1 (en) 2011-01-26 2012-08-02 Zafgen Corporation Tetrazole compounds and methods of making and using same
MX342257B (es) 2011-03-08 2016-09-21 Zafgen Inc Derivados y análogos de oxaspiro [2.5] octano.
EA025526B1 (ru) 2011-05-06 2017-01-30 Зафджен Инк. Частично насыщенные трициклические соединения и способы их получения и применения
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
MX343688B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
JP6035347B2 (ja) 2012-01-18 2016-11-30 ザフゲン,インコーポレイテッド 三環式スルホンアミド化合物ならびにその作製および使用方法
JP2015509102A (ja) 2012-01-18 2015-03-26 ザフゲン,インコーポレイテッド 三環式スルホン化合物並びにその作製および使用方法
AU2013259760A1 (en) 2012-05-07 2014-11-20 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol and methods of making and using same
CA2872876A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
WO2013169860A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
JP6169716B2 (ja) 2012-11-05 2017-07-26 ザフゲン,インコーポレイテッド 肝疾患を治療する方法
AU2013337288A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
CN104870433A (zh) 2012-11-05 2015-08-26 扎夫根股份有限公司 三环化合物及其制备方法和用途
JP2016513722A (ja) 2013-03-14 2016-05-16 ザフゲン,インコーポレイテッド 腎臓病及び他の疾患の治療方法
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
CA2082804A1 (en) * 1990-07-27 1992-01-28 Theodore Maione Methods and compositions for treatment of angiogenic diseases
US5328930A (en) * 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
DK0817626T3 (da) * 1995-03-27 1999-07-12 Assist Publ Hopitaux De Paris Anvendelse af fumagillol og derivater deraf til fremstilling af lægemidler mod tarminfektioner
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
WO1998005293A2 (en) * 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
ES2128846T3 (es) 1999-05-16
AP646A (en) 1998-04-27
IS4557A (is) 1997-09-11
JP3260378B2 (ja) 2002-02-25
AP9701092A0 (en) 1997-10-31
CN1179715A (zh) 1998-04-22
PL183378B1 (pl) 2002-06-28
AU706161B2 (en) 1999-06-10
HUP9801220A2 (hu) 1999-09-28
UA41446C2 (uk) 2001-09-17
US5900431A (en) 1999-05-04
SK130797A3 (en) 1998-03-04
OA10515A (fr) 2002-04-24
HU224028B1 (hu) 2005-05-30
EP0817626A2 (fr) 1998-01-14
JPH11506421A (ja) 1999-06-08
EA000150B1 (ru) 1998-10-29
WO1996030010A3 (fr) 1996-11-28
CA2216623C (en) 2005-05-31
NO315968B1 (no) 2003-11-24
MX9707150A (es) 1998-07-31
CN1072485C (zh) 2001-10-10
FR06C0014I1 (cg-RX-API-DMAC10.html) 2006-11-17
NZ304906A (en) 1999-06-29
WO1996030010A2 (fr) 1996-10-03
SK283883B6 (sk) 2004-04-06
EP0817626B1 (fr) 1998-10-28
CZ304997A3 (en) 1997-12-17
NO974466D0 (no) 1997-09-26
DE69600879D1 (de) 1998-12-03
KR19980703271A (ko) 1998-10-15
DE69600879T2 (de) 1999-06-02
EA199700267A1 (ru) 1998-04-30
KR100286920B1 (ko) 2001-04-16
ATE172641T1 (de) 1998-11-15
HUP9801220A3 (en) 2001-10-29
CA2216623A1 (en) 1996-10-03
AU5278696A (en) 1996-10-16
TR199701048T1 (xx) 1998-01-21
PL322470A1 (en) 1998-02-02
CZ286821B6 (en) 2000-07-12
NO974466L (no) 1997-09-26
DK0817626T3 (da) 1999-07-12
IS2048B (is) 2005-09-15

Similar Documents

Publication Publication Date Title
BR122012014331A2 (cg-RX-API-DMAC10.html)
BRPI9612258B1 (cg-RX-API-DMAC10.html)
BRPI9612138B1 (cg-RX-API-DMAC10.html)
FR06C0014I1 (cg-RX-API-DMAC10.html)
CH0741373H1 (cg-RX-API-DMAC10.html)
BR7501503U (cg-RX-API-DMAC10.html)
BR7502120U (cg-RX-API-DMAC10.html)
BY5258C1 (cg-RX-API-DMAC10.html)
CN3029801S (cg-RX-API-DMAC10.html)
CN3029928S (cg-RX-API-DMAC10.html)
CN3030154S (cg-RX-API-DMAC10.html)
CN3030197S (cg-RX-API-DMAC10.html)
CN3030225S (cg-RX-API-DMAC10.html)
CN3030296S (cg-RX-API-DMAC10.html)
CN3030415S (cg-RX-API-DMAC10.html)
CN3030489S (cg-RX-API-DMAC10.html)
CN3030542S (cg-RX-API-DMAC10.html)
CN3030543S (cg-RX-API-DMAC10.html)
CN3030760S (cg-RX-API-DMAC10.html)
CN3031001S (cg-RX-API-DMAC10.html)
CN3031350S (cg-RX-API-DMAC10.html)
CN3031655S (cg-RX-API-DMAC10.html)
CN3031742S (cg-RX-API-DMAC10.html)
CN3031926S (cg-RX-API-DMAC10.html)
CN3032332S (cg-RX-API-DMAC10.html)